within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BC01_Nebacumab;
model Nebacumab 
   extends Pharmacolibrary.Drugs.ATC.J.J06BC01;

  annotation(Documentation(
    info ="<html><body><p>Nebacumab (Centoxin) is a human monoclonal antibody that was developed for treatment of sepsis caused by gram-negative bacteria, specifically targeting endotoxin. The drug was withdrawn from development due to lack of efficacy and is not approved for clinical use today.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies in humans available. Parameter estimates are extrapolated based on typical IgG1 monoclonal antibody behavior in adults following intravenous dosing.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Nebacumab;
